Genentech Unveils First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
Genentech has unveiled Tecentriq Hybreza™ (atezolizumab and hyaluronidase-tqjs), making it the first and only PD-(L)1 inhibitor available as a subcutaneous (SC) injection in the United States.
Tecentriq Hybreza combines Tecentriq with Halozyme Therapeutics’ Enhanze® drug delivery technology. Tecentriq, a monoclonal antibody, targets the PD-L1 protein found on tumour cells and immune cells within tumours. By binding to PD-L1, Tecentriq blocks its interaction with PD-1 and B7.1 receptors, potentially helping to reactivate T cells and impact healthy cells as well.
The new formulation allows for a subcutaneous injection in just seven minutes, compared to the 30-60 minutes typically required for an intravenous infusion of Tecentriq. Tecentriq Hybreza provides both patients and healthcare professionals with more flexibility, offering a faster, more convenient treatment option while maintaining the proven safety and effectiveness of intravenous Tecentriq.
Tecentriq Hybreza will be available for all intravenous indications approved for adults in the U.S., addressing a range of cancers including lung, liver, skin, and soft tissue. This new formulation enhances accessibility across different healthcare settings.
Tecentriq is used to treat some of the most challenging cancers and was the first immunotherapy approved for early-stage non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and hepatocellular carcinoma (HCC).
It is also approved worldwide, either as a monotherapy or in combination with other treatments, for various cancers such as metastatic NSCLC, metastatic urothelial cancer (mUC), PD-L1-positive metastatic triple-negative breast cancer (TNBC), BRAF V600 mutation-positive advanced melanoma, and alveolar soft part sarcoma (ASPS).
